Secukinumab improves the signs and symptoms of moderate‐to‐severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double‐blind, placebo‐controlled, phase 2 dose‐ranging study. (13th December 2013) - Sigurgeirsson, B.; Kircik, L.; Nemoto, O.; Mikazans, I.; Haemmerle, S.; Thurston, H.J.; Papavassilis, C.; Richards, H.B.